ReviewDrugs1999
Managing resistance to anti-HIV drugs: an important consideration for effective disease management.
Review in Drugs, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.Molecules (Basel, Switzerland) · 2021Article
- Modeling Cumulative Biological Phenomena with Suppes-Bayes Causal Networks.Evolutionary bioinformatics online · 2018Article
- Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania.Drug, healthcare and patient safety · 2018Article
- Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.Molecules (Basel, Switzerland) · 2017Article
- Different frequencies of drug resistance mutations among HIV-1 subtypes circulating in China: a comprehensive study.PloS one · 2014Article
- Emergence of drug resistance-associated mutations in HIV-1 subtype C protease gene in north India.Virus genes · 2013Article
- Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.Retrovirology · 2012Article
- Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis.BMC medical informatics and decision making · 2011Article
- Fluorescent HIV-1 Dimerization Initiation Site: design, properties, and use for ligand discovery.Journal of the American Chemical Society · 2007Article
- Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes.Nucleic acids research · 2003Article
- Enfuvirtide.Drugs · 2003Review
- env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.Antimicrobial agents and chemotherapy · 2002Article
- Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Genotypic testing for human immunodeficiency virus type 1 drug resistance.Clinical microbiology reviews · 2002Review
- Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.Journal of clinical microbiology · 2002Article
- Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.Journal of clinical microbiology · 2000Article
- Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.Antimicrobial agents and chemotherapy · 2000Article
- Production of resistant HIV mutants during antiretroviral therapy.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Review
- The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.AIDS reviews · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current recommendations for the treatment of HIV-infected patients advise highly active antiretroviral therapy (HAART) consisting of combinations of 3 or more drugs to provide long-term clinical benefit. This is because only a complete suppression of virus replication will be able to prevent virus drug resistance, the main cause of drug failure. Virus drug resistance may remain a cause of concern in patients who have already received suboptimal mono- or bitherapy, or for patients who do not experience complete shut-down of virus replication under HAART. For these patients, replacement of one combination therapy regimen by another at drug failure, taking into account the existing resistance profile, will be needed. The development of new drugs will remain necessary for those patients who have failed to respond to all currently available drugs, as will be the institution of more effective and less toxic HAART regimens.
Indexed as
Identifiers
10193687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.